Cagrilintide is not FDA-approved and remains investigational as of 2026
The safest approach is a regulated system where peptides are traceable, independently tested and prescribed within a medical framework
3 Strategic Commercial Expansion in Emerging Markets Extensior will be offered in the familiar 0.25 mg, 0.5 mg, and 1 mg dosage strengths and will be commercialized through a partnership with @Acino, part of @Arcera, to strengthen distribution across South Africa
Yes, the Saxenda brand of liraglutide is approved to be used for weight loss
Not classified as drugs, supplements, or food, and not evaluated by the FDA for diagnosis, treatment, cure, or prevention of any condition